Filipecki Artur, Saksena Sanjeev, Lin Wen Hong
Electrophysiology Research Foundation, Warren, New Jersey, USA.
Am J Cardiol. 2003 Nov 1;92(9):1037-44. doi: 10.1016/j.amjcard.2003.07.004.
Right atrial (RA) maze procedures using linear catheter ablation have had limited efficacy in paroxysmal atrial fibrillation (AF). We hypothesized that "hybrid" therapy using overdrive atrial pacing and antiarrhythmic drugs can improve efficacy of catheter RA maze and expand its role to persistent or permanent AF. Catheter RA maze procedures were performed in 26 patients with persistent or permanent AF refractory to 4.5 +/- 2.1 antiarrhythmic drugs. Overdrive dual-site RA pacing (21 patients) or high RA pacing (5 patients) was continued (n = 11) or instituted periablation (n = 15). All patients continued receiving previously ineffective antiarrhythmic drugs. Freedom from permanent AF (rhythm control), symptomatic and/or asymptomatic AF recurrences, the safety of hybrid therapy, and overall survival were assessed. There was no procedure-related mortality or stroke. Rhythm control was achieved in 24 patients (92%) within 3 months. During long-term follow-up (6 to 49 months, mean 17 +/- 10), rhythm control was maintained in 20 patients (77%). Nine patients (35%) had no AF recurrences, whereas 11 patients maintained rhythm control with infrequent AF recurrences. Device datalogs at the study cut-off point demonstrated no AF events in 6 patients, nonsustained atrial tachycardia in 2 patients, and brief asymptomatic paroxysmal AF in 12 patients. Actuarial patient survival was 95% at 1 year and 74% at 2 years of follow-up. Thus, hybrid therapy utilizing catheter RA maze procedures with overdrive atrial pacing and antiarrhythmic drugs can be performed safely and can reestablish rhythm control in selected patients with refractory persistent or permanent AF.
使用线性导管消融的右心房(RA)迷宫手术对阵发性心房颤动(AF)的疗效有限。我们推测,采用超速心房起搏和抗心律失常药物的“杂交”疗法可提高导管RA迷宫手术的疗效,并将其作用扩展至持续性或永久性AF。对4.5±2.1种抗心律失常药物治疗无效的26例持续性或永久性AF患者进行了导管RA迷宫手术。在消融期间(n = 15)或继续(n = 11)进行超速双部位RA起搏(21例患者)或高位RA起搏(5例患者)。所有患者继续服用先前无效的抗心律失常药物。评估了无永久性AF(节律控制)、有症状和/或无症状AF复发情况、杂交疗法的安全性以及总生存率。未发生与手术相关的死亡或卒中。24例患者(92%)在3个月内实现了节律控制。在长期随访(6至49个月,平均17±10)期间,20例患者(77%)维持了节律控制。9例患者(35%)无AF复发,而11例患者通过不频繁的AF复发维持了节律控制。研究截止点时的设备数据记录显示,6例患者无AF事件,2例患者有非持续性房性心动过速,12例患者有短暂无症状阵发性AF。随访1年时患者精算生存率为95%,2年时为74%。因此,采用导管RA迷宫手术联合超速心房起搏和抗心律失常药物的杂交疗法可安全实施,并可在部分难治性持续性或永久性AF患者中重新建立节律控制。